www.medpagetoday.com ATLANTA -- Atrial fibrillation is both a major stroke risk and a looming public health problem since the risk of afib increases with age, and the standard treatment, warfarin, is often a clinical management challenge. But a number of investigational therapies suggest that a post-warfarin era is beginning. In this MedPage Today InFocus™ report, American College of Cardiology president Ralph Brindis, MD, of the University of California San Francisco, says two new compounds, betrixaban and dabigatran, have "raised the threshold" for anticoagulation therapy.
Tags: medicine, health, Med, Page, Today
No comments:
Post a Comment